Neuralink’s private valuation has climbed sharply in secondary markets to marks between $28.9 billion and $45 billion as of early October 2026, well above its $9.65 billion post-money Series E in June 2025. Trader sentiment reflects accelerating clinical momentum, including October 3 updates showing participants achieving a record 11.32 bits-per-second cursor control and calibration times reduced to as little as 10 minutes weekly after 50,000 hours of neural data. Preclinical Blindsight work and FDA trial expansions add to the narrative, yet the company remains pre-revenue with valuation hinging on infrequent priced rounds or secondary liquidity rather than earnings. With resolution only weeks away on October 31, any near-term catalyst would likely stem from additional implant data or a new funding announcement.